Prof.Dr.med. ID: 6488383
Katja Weisel
Publications
56/m mit Rückenschmerzen und Konzentrationsstörungen
Leypoldt, L. B. & Weisel, K. C., 12.07.2021, In: ONKOLOGE. 2021, 27 supplement issue 1, p. 27-32Research output: SCORING: Contribution to journal › SCORING: Journal article › Education
A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis
Weisel, K., Sonneveld, P., Spencer, A., Beksac, M., Rizzo, M., Xu, Y., Fahrbach, K., Gaudig, M., Slavcev, M., Dearden, L. & Lam, A., 01.2019, In: LEUKEMIA LYMPHOMA. 60, 1, p. 151-162 12 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial
Weisel, K. C., Scheid, C., Zago, M., Besemer, B., Mai, E. K., Haenel, M., Duerig, J., Munder, M., Lindemann, H-W., Seckinger, A., Kunz, C., Benner, A., Hose, D., Jauch, A., Salwender, H. & Goldschmidt, H., 08.04.2019, In: BLOOD CANCER J. 9, 4, p. 45Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., Magen, H., Larocca, A., Laubach, J. P., Petrucci, M. T., Reece, D., White, D., Mateos, M-V., Špička, I., Lazaroiu, M., Berdeja, J., Kaufman, J. L., Jou, Y-M., Ganetsky, A., Popa McKiver, M., Lonial, S., Weisel, K. & ELOQUENT-1 investigators, 06.2022, In: LANCET HAEMATOL. 9, 6, p. e403-e414Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
Goldschmidt, H., Mai, E. K., Bertsch, U., Fenk, R., Nievergall, E., Tichy, D., Besemer, B., Dürig, J., Schroers, R., von Metzler, I., Hänel, M., Mann, C., Asemissen, A. M., Heilmeier, B., Weinhold, N., Huhn, S., Kriegsmann, K., Luntz, S. P., Holderried, T. A. W., Trautmann-Grill, K., Gezer, D., Klaiber-Hakimi, M., Müller, M., Khandanpour, C., Knauf, W., Scheid, C., Munder, M., Geer, T., Riesenberg, H., Thomalla, J., Hoffmann, M., Raab, M. S., Salwender, H. J., Weisel, K. C. & German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators, 11.2022, In: LANCET HAEMATOL. 9, 11, p. e810-e821Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice
Mateos, M-V., Weisel, K., Martin, T., Berdeja, J. G., Jakubowiak, A., Stewart, A. K., Jagannath, S., Lin, Y., Diels, J., Ghilotti, F., Thilakarathne, P., Perualila, N. J., Cabrieto, J., Haefliger, B., Erler-Yates, N., Hague, C., Jackson, C. C., Schecter, J. M., Strulev, V., Nesheiwat, T., Pacaud, L., Einsele, H. & Moreau, P., 01.08.2023, In: HAEMATOLOGICA. 108, 8, p. 2192-2204 13 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
Neben, K., Lokhorst, H. M., Jauch, A., Bertsch, U., Hielscher, T., van der Holt, B., Salwender, H., Blau, I. W., Weisel, K., Pfreundschuh, M., Scheid, C., Dührsen, U., Lindemann, W., Schmidt-Wolf, I. G. H., Peter, N., Teschendorf, C., Martin, H., Haenel, M., Derigs, H. G., Raab, M. S., Ho, A. D., van de Velde, H., Hose, D., Sonneveld, P. & Goldschmidt, H., 26.01.2012, In: BLOOD. 119, 4, p. 940-8 9 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis
Moreau, P., Dimopoulos, M. A., Richardson, P. G., Siegel, D. S., Cavo, M., Corradini, P., Weisel, K., Delforge, M., O'Gorman, P., Song, K., Chen, C., Bahlis, N., Oriol, A., Hansson, M., Kaiser, M., Anttila, P., Raymakers, R., Joao, C., Cook, G., Sternas, L., Biyukov, T., Slaughter, A., Hong, K., Herring, J., Yu, X., Zaki, M. & San-Miguel, J., 09.2017, In: EUR J HAEMATOL. 99, 3, p. 199-206 8 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens: entity-specific dividing lines and "pan-leukemia" antigens
Backert, L., Kowalewski, D. J., Walz, S., Schuster, H., Berlin, C., Neidert, M. C., Schemionek, M., Brümmendorf, T. H., Vucinic, V., Niederwieser, D., Kanz, L., Salih, H. R., Kohlbacher, O., Weisel, K., Rammensee, H-G., Stevanovic, S. & Walz, J. S., 04.07.2017, In: ONCOTARGET. 8, 27, p. 43915-43924 10 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide Exposure
Davies, F. E., Leleu, X., Vogel, P., Dhanasiri, S., Le Nouveau, P. & Weisel, K., 11.2023, In: CL LYMPH MYELOM LEUK. 23, 11, p. 829-837.e1Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma
Weisel, K. C., Dimopoulos, M. A., Moreau, P., Lacy, M. Q., Song, K. W., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., Alegre, A., Chen, C., Cavo, M., Garderet, L., Ivanova, V., Martinez-Lopez, J., Knop, S., Yu, X., Hong, K., Sternas, L., Jacques, C., Zaki, M. H. & San Miguel, J., 07.2016, In: HAEMATOLOGICA. 101, 7, p. 872-8 7 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma
Rodríguez Otero, P., Towle, K., Cope, S., Caisip, C., Davies, F. E., Delforge, M., Weisel, K., Marshall, T. S., Karampampa, K., Ayers, D., Mojebi, A., Braverman, J., Farrell, J. & Dhanda, D., 2023, In: LEUKEMIA LYMPHOMA. 64, 11, p. 1864-1869 6 p.Research output: SCORING: Contribution to journal › Letter › Research › peer-review
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes
Leleu, X., Martin, T., Weisel, K., Schjesvold, F., Iida, S., Malavasi, F., Manier, S., Chang-Ki Min, Ocio, E. M., Pawlyn, C., Perrot, A., Quach, H., Richter, J., Spicka, I., Yong, K. & Richardson, P. G., 10.2022, In: ANN HEMATOL. 101, 10, p. 2123-2137 15 p.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma
Giesen, N., Chatterjee, M., Scheid, C., Poos, A. M., Besemer, B., Miah, K., Benner, A., Becker, N., Moehler, T., Metzler, I., Khandanpour, C., Seidel-Glaetzer, A., Trautmann-Grill, K., Kortüm, K. M., Müller-Tidow, C., Mechtersheimer, G., Goeppert, B., Stenzinger, A., Weinhold, N., Goldschmidt, H., Weisel, K. C. & Raab, M. S., 06.04.2023, In: BLOOD. 141, 14, p. 1685-1690 6 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
D'Souza, A., Shah, N., Rodriguez, C., Voorhees, P. M., Weisel, K., Bueno, O. F., Pothacamury, R. K., Freise, K. J., Yue, S., Ross, J. A., Polepally, A. R., Talati, C., Lee, S., Jin, Z., Buelow, B., Vij, R. & Kumar, S., 01.11.2022, In: J CLIN ONCOL. 40, 31, p. 3576-3586 11 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas
Weidmann, E., Hess, G., Chow, K. U., Krause, S. W., Subklewe, M., Kruse, J., Weisel, K. C., Soekler, M., Kim, S-Z., Napieralski, S., Rech, J., Dreyling, M., Jäger, E. & Mitrou, P. S., 03.2010, In: LEUKEMIA LYMPHOMA. 51, 3, p. 447-55 9 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation
Weisel, K., Doyen, C., Dimopoulos, M., Yee, A., Lahuerta, J. J., Martin, A., Travers, K., Druyts, E., Toor, K., Abildgaard, N., Lu, J., Van Droogenbroeck, J., Geraldes, C., Petrini, M., Voillat, L., Voog, E. & Facon, T., 01.2017, In: LEUKEMIA LYMPHOMA. 58, 1, p. 153-161 9 p.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects
Jansen, L., Merz, M., Engelhardt, M., Weisel, K., Scheid, C., Straka, C., Langer, C., Salwender, H., Einsele, H., Kröger, N., Beelen, D. W., Dreger, P., Goldschmidt, H., Brenner, H. & German National Registry for Stem Cell Transplants (DRST), 10.2020, In: LEUKEMIA LYMPHOMA. 61, 10, p. 2365-2374 10 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Automated "Bone Subtraction" Image Analysis Software Package for Improved and Faster CT Monitoring of Longitudinal Spine Involvement in Patients with Multiple Myeloma
Horger, M., Ditt, H., Liao, S., Weisel, K., Fritz, J., Thaiss, W. M., Kaufmann, S., Nikolaou, K. & Kloth, C., 05.2017, In: ACAD RADIOL. 24, 5, p. 623-632 10 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
BCMA x CD3 T-cell engager in a patient with penta-refractory multiple myeloma and HIV: a clinical and immunological report
Cords, L., Schaefers, C., Kamili, A., Hoffmann, C., Cichutek, S., Haag, F., Polywka, S., Bokemeyer, C., Leypoldt, L. B., Alsdorf, W., Schulze zur Wiesch, J. & Weisel, K. C., 01.09.2024, In: HAEMATOLOGICA. 109, 9, p. 3071-3077 7 p.Research output: SCORING: Contribution to journal › Case report › Research › peer-review
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma
Mateos, M. V., Weisel, K., Terpos, E., Delimpasi, S., Kastritis, E., Zamagni, E., Delforge, M., Ocio, E., Katodritou, E., Gay, F., Larocca, A., Leleu, X., Otero, P. R., Schjesvold, F., Cavo, M. & Dimopoulos, M. A., 01.07.2024, In: HAEMATOLOGICA. 109, 7, p. 2337-2340 4 p.Research output: SCORING: Contribution to journal › Letter › Research › peer-review
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A-O., Callander, N., Lendvai, N., Sborov, D., Suvannasankha, A., Weisel, K., Karlin, L., Libby, E., Arnulf, B., Facon, T., Hulin, C., Kortüm, K. M., Rodríguez-Otero, P., Usmani, S. Z., Hari, P., Baz, R., Quach, H., Moreau, P., Voorhees, P. M., Gupta, I., Hoos, A., Zhi, E., Baron, J., Piontek, T., Lewis, E., Jewell, R. C., Dettman, E. J., Popat, R., Esposti, S. D., Opalinska, J., Richardson, P. & Cohen, A. D., 02.2020, In: LANCET ONCOL. 21, 2, p. 207-221 15 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design
Nooka, A. K., Weisel, K., van de Donk, N. W., Routledge, D., Otero, P. R., Song, K., Quach, H., Callander, N., Minnema, M. C., Trudel, S., Jackson, N. A., Ahlers, C. M., Im, E., Cheng, S., Smith, L., Hareth, N., Ferron-Brady, G., Brouch, M., de Oca, R. M., Paul, S., Holkova, B., Gupta, I., Kremer, B. E. & Richardson, P., 06.2021, In: FUTURE ONCOL. 17, 16, p. 1987-2003 17 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee
Holstein, S. A., Avet-Loiseau, H., Hahn, T., Ho, C. M., Lohr, J. G., Munshi, N. C., Paiva, B., Pasquini, M. C., Tario, J. D., Usmani, S. Z., Wallace, P. K., Weisel, K. & McCarthy, P. L., 04.2018, In: BIOL BLOOD MARROW TR. 24, 4, p. 641-648 8 p.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
Brauneck, F., Weimer, P., Schulze zur Wiesch, J., Weisel, K. C., Leypoldt, L. B., Vohwinkel, G., Fritzsche, B., Bokemeyer, C., Wellbrock, J. & Fiedler, W., 08.11.2021, In: FRONT MED-LAUSANNE. 8, p. 763773 10 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
Mai, E. K., Miah, K., Bertsch, U., Dürig, J., Scheid, C., Weisel, K. C., Kunz, C., Munder, M., Lindemann, H-W., Merz, M., Hose, D., Jauch, A., Seckinger, A., Luntz, S., Sauer, S., Fuhrmann, S., Brossart, P., Elmaagacli, A., Goerner, M., Bernhard, H., Hoffmann, M., Raab, M. S., Blau, I. W., Hänel, M., Benner, A., Salwender, H. J., Goldschmidt, H. & German-speaking Myeloma Multicenter Group (GMMG), 03.2021, In: LEUKEMIA. 35, 3, p. 809-822 14 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma
Mai, E. K., Hielscher, T., Bertsch, U., Schlenzka, J., Salwender, H. J., Munder, M., Gerecke, C., Dührsen, U., Brossart, P., Neben, K., Hillengass, J., Raab, M. S., Merz, M., Baertsch, M-A., Jauch, A., Hose, D., Martin, H., Lindemann, H-W., Blau, I. W., Scheid, C., Weisel, K. C., Goldschmidt, H. & German-speaking Myeloma Multicenter Group (GMMG), 01.2019, In: LEUKEMIA. 33, 1, p. 258-261 4 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial
Scheid, C., Sonneveld, P., Schmidt-Wolf, I. G. H., van der Holt, B., el Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Blau, I. W., Vellenga, E., Weisel, K., Pfreundschuh, M., Jie, K-S., Neben, K., van de Velde, H., Duehrsen, U., Schaafsma, M. R., Lindemann, W., Kersten, M. J., Peter, N., Hänel, M., Croockewit, S., Martin, H., Wittebol, S., Bos, G. M., van Marwijk-Kooy, M., Wijermans, P., Goldschmidt, H. & Lokhorst, H. M., 01.2014, In: HAEMATOLOGICA. 99, 1, p. 148-54 7 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial
Goldschmidt, H., Lokhorst, H. M., Mai, E. K., van der Holt, B., Blau, I. W., Zweegman, S., Weisel, K. C., Vellenga, E., Pfreundschuh, M., Kersten, M. J., Scheid, C., Croockewit, S., Raymakers, R., Hose, D., Potamianou, A., Jauch, A., Hillengass, J., Stevens-Kroef, M., Raab, M. S., Broijl, A., Lindemann, H. W., Bos, G. M. J., Brossart, P., van Marwijk Kooy, M., Ypma, P., Duehrsen, U., Schaafsma, R. M., Bertsch, U., Hielscher, T., Jarari, L., Salwender, H. J. & Sonneveld, P., 02.2018, In: LEUKEMIA. 32, 2, p. 383-390 8 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial
Sonneveld, P., Schmidt-Wolf, I. G. H., van der Holt, B., El Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Vellenga, E., Broyl, A., Blau, I. W., Weisel, K. C., Wittebol, S., Bos, G. M. J., Stevens-Kroef, M., Scheid, C., Pfreundschuh, M., Hose, D., Jauch, A., van der Velde, H., Raymakers, R., Schaafsma, M. R., Kersten, M-J., van Marwijk-Kooy, M., Duehrsen, U., Lindemann, W., Wijermans, P. W., Lokhorst, H. M. & Goldschmidt, H. M., 20.08.2012, In: J CLIN ONCOL. 30, 24, p. 2946-55 10 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Can whole-body low-dose multidetector CT exclude the presence of myeloma bone disease in patients with monoclonal gammopathy of undetermined significance (MGUS)?
Spira, D., Weisel, K., Brodoefel, H., Schulze, M., Kaufmann, S. & Horger, M., 01.2012, In: ACAD RADIOL. 19, 1, p. 89-94 6 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison
Weisel, K., Nooka, A. K., Terpos, E., Spencer, A., Goldschmidt, H., Dirnberger, F., DeCosta, L., Yusuf, A. & Kumar, S., 08.2022, In: LEUKEMIA LYMPHOMA. 63, 8, p. 1887-1896 10 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini
Kowalewski, D. J., Walz, S., Backert, L., Schuster, H., Kohlbacher, O., Weisel, K., Rittig, S. M., Kanz, L., Salih, H. R., Rammensee, H-G., Stevanović, S. & Stickel, J. S., 08.04.2016, In: BLOOD CANCER J. 6, p. e411Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Dimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hájek, R., Facon, T., Ludwig, H., Oriol, A., Goldschmidt, H., Rosiñol, L., Straub, J., Suvorov, A., Araujo, C., Rimashevskaya, E., Pika, T., Gaidano, G., Weisel, K., Goranova-Marinova, V., Schwarer, A., Minuk, L., Masszi, T., Karamanesht, I., Offidani, M., Hungria, V., Spencer, A., Orlowski, R. Z., Gillenwater, H. H., Mohamed, N., Feng, S., Chng, W-J. & ENDEAVOR Investigators, 01.2016, In: LANCET ONCOL. 17, 1, p. 27-38 12 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials
Weisel, K., Majer, I., DeCosta, L., Oriol, A., Goldschmidt, H., Ludwig, H., Campioni, M., Szabo, Z. & Dimopoulos, M., 01.2020, In: LEUKEMIA LYMPHOMA. 61, 1, p. 37-46 10 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup
Ludwig, H., Dimopoulos, M. A., Moreau, P., Chng, W-J., Goldschmidt, H., Hájek, R., Facon, T., Pour, L., Niesvizky, R., Oriol, A., Rosiñol, L., Suvorov, A., Gaidano, G., Pika, T., Weisel, K., Goranova-Marinova, V., Palumbo, A., Gillenwater, H. H., Mohamed, N., Aggarwal, S., Feng, S. & Joshua, D., 10.2017, In: LEUKEMIA LYMPHOMA. 58, 10, p. 2501-2504 4 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloman: indirect treatment comparisona
Weisel, K., Dimopoulos, M. A., Beksac, M., Leleu, X., Richter, J., Heeg, B., Patel, S., Majer, I., McFadden, I. & Mikhael, J., 04.2024, In: LEUKEMIA LYMPHOMA. 65, 4, p. 481-492 12 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy
Quach, H., Nooka, A., Samoylova, O., Venner, C. P., Kim, K., Facon, T., Spencer, A., Usmani, S. Z., Grosicki, S., Suzuki, K., Delimpasi, S., Weisel, K., Obreja, M., Zahlten-Kumeli, A. & Mateos, M-V., 08.2021, In: BRIT J HAEMATOL. 194, 4, p. 784-788 5 p.Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
Dimopoulos, M., Quach, H., Mateos, M-V., Landgren, O., Leleu, X., Siegel, D., Weisel, K., Yang, H., Klippel, Z., Zahlten-Kumeli, A. & Usmani, S. Z., 18.07.2020, In: LANCET. 396, 10245, p. 186-197 12 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study
Goldschmidt, H., Moreau, P., Ludwig, H., Niesvizky, R., Chng, W-J., Joshua, D., Weisel, K., Spencer, A., Orlowski, R. Z., Feng, S., Iskander, K. S. & Dimopoulos, M. A., 06.2018, In: LEUKEMIA LYMPHOMA. 59, 6, p. 1364-1374 11 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
Chng, W-J., Goldschmidt, H., Dimopoulos, M. A., Moreau, P., Joshua, D., Palumbo, A., Facon, T., Ludwig, H., Pour, L., Niesvizky, R., Oriol, A., Rosiñol, L., Suvorov, A., Gaidano, G., Pika, T., Weisel, K., Goranova-Marinova, V., Gillenwater, H. H., Mohamed, N., Feng, S., Aggarwal, S. & Hájek, R., 06.2017, In: LEUKEMIA. 31, 6, p. 1368-1374 7 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Dimopoulos, M. A., Goldschmidt, H., Niesvizky, R., Joshua, D., Chng, W-J., Oriol, A., Orlowski, R. Z., Ludwig, H., Facon, T., Hajek, R., Weisel, K., Hungria, V., Minuk, L., Feng, S., Zahlten-Kumeli, A., Kimball, A. S. & Moreau, P., 10.2017, In: LANCET ONCOL. 18, 10, p. 1327-1337 11 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy
Pape, L. J., Hambach, J., Gebhardt, A. J., Rissiek, B., Stähler, T., Tode, N., Khan, C., Weisel, K., Adam, G., Koch-Nolte, F. & Bannas, P., 2022, In: FRONT IMMUNOL. 13, 1010270.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
CD8+ CD28- regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study
Kriegsmann, K., Ton, G. N. H. Q., Awwad, M. H. S., Benner, A., Bertsch, U., Besemer, B., Hänel, M., Fenk, R., Munder, M., Dürig, J., Blau, I. W., Huhn, S., Hose, D., Jauch, A., Mann, C., Weinhold, N., Scheid, C., Schroers, R., von Metzler, I., Schieferdecker, A., Thomalla, J., Reimer, P., Mahlberg, R., Graeven, U., Kremers, S., Martens, U. M., Kunz, C., Hensel, M., Seidel-Glätzer, A., Weisel, K. C., Salwender, H. J., Müller-Tidow, C., Raab, M. S., Goldschmidt, H., Mai, E. K. & Hundemer, M., 07.2024, In: LEUKEMIA. 38, 7, p. 1621-1625 5 p.Research output: SCORING: Contribution to journal › Letter › Research › peer-review
Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients
Kriegsmann, K., Baertsch, M-A., Awwad, M. H. S., Merz, M., Hose, D., Seckinger, A., Jauch, A., Becker, N., Benner, A., Raab, M. S., Hillengass, J., Bertsch, U., Dürig, J., Salwender, H. J., Hänel, M., Fenk, R., Munder, M., Weisel, K., Müller-Tidow, C., Goldschmidt, H. & Hundemer, M., 29.01.2019, In: BLOOD CANCER J. 9, 2, p. 13Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS
Qian, X., Dimopoulos, M. A., Amatangelo, M., Bjorklund, C., Towfic, F., Flynt, E., Weisel, K. C., Ocio, E. M., Yu, X., Peluso, T., Sternas, L., Zaki, M., Moreau, P. & Thakurta, A., 02.2019, In: LEUKEMIA LYMPHOMA. 60, 2, p. 462-470 9 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Challenges in treatment of patients with acute leukemia and COVID-19: a series of 12 patients
Ghandili, S., Pfefferle, S., Roedl, K., Sonnemann, P., Karagiannis, P., Boenisch, O., Kluge, S., Schmiedel, S., Ittrich, H., Rohde, H., Lütgehetmann, M., Weisel, K., Bokemeyer, C., Wichmann, D., Fiedler, W., Jarczak, D. & Modemann, F., 08.12.2020, In: Blood Adv. 4, 23, p. 5936-5941 6 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study
Mateos, M-V., Weisel, K., Diels, J., Arribas, A., Tamayo, M., Schecter, J. M., Roccia, T., Haddad, I., Pacaud, L. & Moreau, P., 04.2024, In: CL LYMPH MYELOM LEUK. 24, 4, p. 224-231.e2Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial
Huhn, S., Weinhold, N., Nickel, J., Pritsch, M., Hielscher, T., Hummel, M., Bertsch, U., Huegle-Doerr, B., Vogel, M., Angermund, R., Hänel, M., Salwender, H. J., Weisel, K., Dürig, J., Görner, M., Kirchner, H., Peter, N., Graeven, U., Lordick, F., Hoffmann, M., Reimer, P., Blau, I. W., Jauch, A., Dembowsky, K., Möhler, T., Wuchter, P. & Goldschmidt, H., 08.2017, In: BONE MARROW TRANSPL. 52, 8, p. 1194-1198 5 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era
Zago, M., Adam, P., Goldschmidt, H., Fend, F., Kanz, L. & Weisel, K., 02.2014, In: CL LYMPH MYELOM LEUK. 14, 1, p. e7-e11Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review